Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Helomics Corporation
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
Ambrx, Arcus, Cleave Biosciences, InflaRx, MonoSol Rx, Nevakar and Tioma Therapeutics were among firms raising more than $30m in venture funding in July and August. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive review of emerging biopharmaceutical companies that have received venture funding during the past two months.
The device IPO class of 2014 gained on share price, with several outperforming by more than 100%, and market caps for larger companies have grown at a rapid pace.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced October-November 2014.
- Contract Research, Toxicology Testing-CRO
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Precision Therapeutics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.